Synthetic 44-amino-acid peptide
Tesamorelin
Growth hormone-releasing factor analog
FDA-approved for a narrow indicationAn FDA-approved prescription peptide for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
FULL RESEARCH GRAPHIC
Tesamorelin research overview
A dedicated overview of tesamorelin's narrow approved indication, monitoring context, and the 5 mg research vial.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
FDA-approved for a narrow indicationThe approved label explicitly says tesamorelin is not indicated for weight-loss management and notes that long-term cardiovascular safety is not established.
BOUNDARY CHECK
CONTEXT REQUIREDEvidence for a narrow clinical indication should not be generalized into a bodybuilding or routine fat-loss protocol.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
20 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
5 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
Egrifta WR label: 1.28 mg once daily
Egrifta WR is labeled at 1.28 mg subcutaneously once daily for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight-loss management.
FDA prescribing information — Egrifta WR ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.